Menin-MLL protein inhibitor as well as pharmaceutical composition and application thereof

CN118930548APending Publication Date: 2024-11-12SCINNOHUB PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410573604.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

进一步的研究发现,这些耐药的患者发生了MEN1基因突变,导致Menin抑制剂不能很好的与Menin蛋白地结合,因此开发能够与Menin突变蛋白结合的抑制剂显得尤为重要,也将给这部分耐药的病人带来治愈希望

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930548A_ABST
    Figure CN118930548A_ABST
Patent Text Reader

Abstract

The invention provides a compound as shown in a formula (I), pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof, a pharmaceutical composition containing the compound, and application of the compound and the pharmaceutically acceptable salt, hydrate, isomer, prodrug or the mixture thereof in preparation of drugs for preventing or treating related diseases caused by interaction with Menin-MLL protein. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a Menin-MLL protein inhibitor, a pharmaceutical composition containing the same, and use of the same in preparing a drug for preventing or treating diseases related to the interaction of the Menin-MLL protein. Background Art

[0002] MLL (Mixed Lineage Leukemia) protein is a histone methyltransferase, also known as KMT2A (Histone-lysine N-methyltransferase 2A). MLL rearranged (MLL-r) leukemia is caused by the translocation of the 11q23 chromosome locus containing the KMT2A gene. It is known that this chromosomal translocation can produce more than 60 oncogenic fusion proteins - formed by the amino terminus of MLL fused with a variety of different proteins, among which the MLL-AF4 / 9 fusion mutation is the most malignant. MLL-r leukemia accounts for 5% to 10% of acute leukemia in adults and 70% of acute leukemia in infants. Currently, there are limited treatment options, mostly chemotherapy drugs, with poor prognosis and high recurrence.

[0003] Menin is a protein mainly localized in the nucleus. It is encoded by the Multiple Endocrine Neoplasia Type 1 (MEN1) gene and is an important cofactor of the oncogenic MLL-r fusion protein. It has a high affinity with the MLL-r protein. After binding to the MLL-r protein, Menin recruits chromatin modification enzymes such as Dot1L or pTEFb complex, leading to enhanced transcription of genes including HOXA and MEIS1. The abnormal expression of these genes hinders the differentiation of hematopoietic cells and promotes their proliferation. In vitro and in vivo experiments have shown that Menin inhibitors can disrupt the interaction between Menin and MLL-r and specifically lead to growth inhibition and apoptosis of leukemia cells carrying MLL-r mutations (Cancer Cell 36, 660–673). Studies have also found that Menin inhibitors are also effective against leukemias with NPM1 gene mutations, which account for about 20-30% of acute myeloid leukemia patients (Science 367, 586–590).

[0004] Currently, several Menin inhibitors are being studied in phase 1 / 2 clinical trials for patients with relapsed / refractory acute leukemia who carry MLL-r or NPM1 mutations, such as Syndax's SNDX-5613, Kura Oncology's KO-539, and Daichi Sankyo Group's DS-1594b. In a clinical trial called AUGMENT-101, 53% of the 60 evaluable patients responded to the drug, but after the second treatment cycle, some patients developed resistance to SNDX-5613 (Nature 615, 913–919). Further studies have found that these resistant patients have MEN1 gene mutations, which prevent Menin inhibitors from binding well to Menin proteins. Therefore, it is particularly important to develop inhibitors that can bind to Menin mutant proteins, which will also bring hope of cure to these resistant patients.

[0005] In addition, excessive expression of Menin can lead to the blockage of β-cell proliferation, resulting in relatively insufficient insulin secretion. A Menin-MLL inhibitor has been shown to enhance β-cell proliferation, thus providing the possibility of application in the field of diabetes. Currently, one compound, BMF-219, is undergoing phase 2 clinical studies for type 2 diabetes.

[0006] Cardiotoxicity of drugs, especially arrhythmias caused by prolonged QT interval, has become a major issue threatening the safety of public medication, and is also a drug cardiac safety issue that is widely concerned by drug regulatory authorities and new drug research and development companies. The protein product encoded by the hERG gene is a key membrane-bound potassium ion channel in myocardial tissue, which is controlled by membrane potential and regulates the outflow of potassium ions from cells in a gated manner. When the compound binds to the hERG potassium channel, it blocks the outflow of potassium ions and prolongs the repolarization time of myocardial cells, which is reflected in the electrocardiogram as a prolonged QT interval. In drug development, it is extremely important to determine the potential of candidate compounds to block the hERG channel. There is an urgent need to develop compounds that cause minimal blockage of the hERG channel to reduce the risk of clinical medication. Summary of the invention

[0007] One of the objects of the present invention is to provide a compound represented by formula I, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof:

[0008]

[0009] Wherein R is -LX; n = 0 or 1;

[0010] When n=1,

[0011] L is selected from C1-C6 alkyl, 3-7 membered monocycloalkyl, 6-10 membered cycloalkyl, 6-10 membered bridged cycloalkyl, 6-10 membered cycloheteroalkyl, 3-7 membered heterocycloalkyl, 6-14 membered aryl, 5-12 membered heteroaryl; optionally, the 6-14 membered aryl or 5-12 membered heteroaryl is replaced by one or more selected from C1-C3 alkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, C1-C3 haloalkyl, cyano, halogen, -NHCOR o , R y CO-、-(CH2)mCONR p R q wherein Ro is selected from C1-C6 alkyl, 3-6-membered cycloalkyl or heterocycloalkyl or -N(CH3)2; Ry is selected from C1-C6 alkyl, 5-7-membered aryl or heteroaryl; R p , R q Each is independently selected from H or C1-C3 alkyl.

[0012] X is selected from -NHSO2Y1, -NHCOY2 or absent.

[0013] Wherein Y1 is selected from C1-C6 alkyl, 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, -NR1R2, 6-14 membered aryl, 5-12 membered heteroaryl.

[0014] wherein when Y1 is selected from 3-7 membered cycloalkyl or 3-7 membered heterocycloalkyl, each of which is optionally substituted by one or more groups selected from C1-C6 alkyl, halogen, cyano, C1-C6 alkoxy, -NRvCOR1, amino, hydroxyl or -NR1R2; wherein when Y1 is selected from 6-14 membered aryl or 5-12 membered heteroaryl, each of which is optionally substituted by one or more R x The group is substituted, the R x The group is selected from C1-C6 alkyl, cyano, halogen, C1-C6 alkoxy, -NR1COR2, C2-C6 alkynyl, amino, hydroxyl, -NR1R2 or C2-C6 alkenyl substituted groups, or the R x The group forms a 9-10-membered ring with Y1; R v Selected from H or C1-C3 alkyl.

[0015] Wherein Y2 is selected from C1-C6 alkyl or NR1R2; R1 or R2 are each independently selected from H or C1-C3 alkyl.

[0016] When n=0,

[0017] L represents a chemical bond, and X represents -COY3.

[0018] Alternatively, L represents a chemical bond and X is

[0019] Where a is 0, 1 or 2.

[0020] R3 is a C1-C3 alkyl group, R3 can be substituted by one or more R5 at any possible position, and R5 can be independently selected from halogen, cyano, hydroxyl, amino, and carboxyl.

[0021] Alternatively, R3 is selected from NR6R7, and R6 and R7 can be independently selected from H, C1-C3 alkyl, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl. In some specific embodiments, R6 and R7 are both H; in some specific embodiments, R6 is H, and R7 is selected from C1-C3 alkyl, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl. In some specific embodiments, R6 is H, and R7 is selected from methyl, ethyl, n-propyl, isopropyl or cyclopropyl.

[0022] R4 is selected from H or C1-C3 alkyl.

[0023] Y3 is selected from 3-7 membered cycloalkyl, 4-10 membered heterocycloalkyl, 5-8 membered aryl, 5-8 membered heteroaryl, 5-7 membered aryl and 5-7 membered heterocyclyl.

[0024] Alternatively, Y3 is selected from 3-12 membered cycloalkyl or heterocycloalkyl, which may be monocyclic or polycyclic.

[0025] Alternatively, Y3 is selected from a 5-16 membered aryl or heteroaryl group, wherein the aryl or heteroaryl group may be monocyclic or polycyclic, and at least part of the polycyclic rings are aromatic.

[0026] Optionally, Y3 is further substituted by one or more groups selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-6-membered cycloalkyl, 5-8-membered aryl, 5-7-membered heteroaryl, halogen, cyano, amino, carboxyl, C1-C6 alkoxy, RyCO-. Ry can be selected from C1-C6 alkyl, C5-C7 aryl or heteroaryl. The above heterocycloalkyl and heteroaryl contain 1-3 heteroatoms, and the heteroatoms are independently selected from N, O, or S.

[0027] ------ represents possible chemical bonds.

[0028] Another object of the present application is to provide a compound shown in formula II, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof:

[0029]

[0030] Wherein Y1 is selected from C1-C6 alkyl, 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, -NR1R2, 6-14 membered aryl, 5-12 membered heteroaryl.

[0031] Wherein when Y1 is selected from 3-7 membered cycloalkyl or 3-7 membered heterocycloalkyl, each is optionally substituted by one or more groups selected from C1-C6 alkyl, halogen, cyano, C1-C6 alkoxy, -NHCOR1, amino, hydroxyl or NR1R2; wherein when Y1 is selected from 6-14 membered aryl or 5-12 membered heteroaryl, each is optionally substituted by one or more Rx groups, wherein the Rx groups are selected from C1-C6 alkyl, cyano, halogen, C1-C6 alkoxy, -NR1COR2, C2-C6 alkynyl, amino, hydroxyl, NR1R2 or C2-C6 alkenyl substituted groups, or the Rx groups form a 9-10 membered ring with Y1.

[0032] The 3-7 membered heterocycloalkyl or 5-12 membered heteroaryl each independently contains 1-3 heteroatoms selected from N, O or S.

[0033] R1 or R2 are each independently selected from H or C1-C3 alkyl;

[0034] ------ represents possible chemical bonds.

[0035] The present application also provides a compound represented by formula III, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof:

[0036]

[0037] wherein Y3 is selected from 3-7 membered cycloalkyl, 4-10 membered heterocycloalkyl, 5-8 membered aryl, 5-8 membered heteroaryl, 5-7 membered aryl and 5-7 membered heterocycloalkyl.

[0038] or Y3 is selected from 3-12 membered cycloalkyl or heterocycloalkyl, the cycloalkyl or heterocycloalkyl may be monocyclic or polycyclic. or Y3 is selected from 5-16 membered aryl or heteroaryl, the aryl or heteroaryl may be monocyclic or polycyclic, at least part of the polycyclic has aromaticity.

[0039] Optionally, Y3 is further substituted by one or more groups selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl, 5-8 membered aryl, 5-7 membered heteroaryl, halogen, cyano, amino, carboxyl, C1-C6 alkoxy.

[0040] The heterocycloalkyl and heteroaryl groups each independently contain 1 to 3 heteroatoms selected from N, O, or S.

[0041] ------ represents possible chemical bonds.

[0042] The present invention also provides a compound represented by formula IV, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof:

[0043]

[0044] Where a is 0, 1 or 2;

[0045] R3 is a C1-C3 alkyl group, R3 can be substituted by one or more R5 at any possible position, and R5 can be independently selected from halogen, cyano, hydroxyl, amino, and carboxyl.

[0046] Alternatively, R3 is selected from NR6R7, and R6 and R7 may be independently selected from H, C1-C3 alkyl, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl.

[0047] R4 is selected from H or C1-C3 alkyl.

[0048] Y3 is selected from 3-12 membered cycloalkyl or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl may be monocyclic or polycyclic;

[0049] Or Y3 is selected from 5-16 membered aryl or heteroaryl groups, wherein the aryl or heteroaryl groups may be monocyclic or polycyclic, and at least part of the polycyclic groups are aromatic.

[0050] Optionally, Y3 is further substituted by one or more selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl, 5-8 membered aryl, 5-7 membered heteroaryl, halogen, cyano, amino, C1-C6 alkoxy, R y CO-substituted; wherein R y It can be selected from C1-C6 alkyl, C5-C7 aryl or heteroaryl.

[0051] The heterocycloalkyl and heteroaryl groups each independently contain 1 to 3 heteroatoms selected from N, O, or S.

[0052] In certain specific embodiments, L is selected from 3-6 membered monocycloalkyl, 6-10 membered cycloalkyl, and X is selected from -NHSO2Y1, -NHCOY2.

[0053] In certain specific embodiments, L is selected from 6-10 membered aryl, 5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, or S, or 6-10 membered heterocycloheteroalkyl, and X is absent.

[0054] In certain embodiments, L is selected from cyclohexyl, oxacyclohexyl, cyclopropyl, tert-butyl, phenyl, indazolyl, oxoindoleyl, 1,3-dihydro-oxo-benzimidazolyl.

[0055] In certain embodiments, when L is selected from oxacyclohexyl, C1-C6 alkyl, cyclopropyl, phenyl, indazolyl, oxoindoleyl, 1,3-dihydro-oxo-benzimidazolyl, X is absent.

[0056] In certain embodiments, X is absent, L is phenyl, and may be replace.

[0057] In certain specific embodiments, Y1 is selected from C1-C3 alkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered aryl or 5-10 membered heteroaryl.

[0058] In certain specific embodiments, Y1 is selected from methyl, ethyl, propyl, isopropyl, tert-butyl, azetidinyl, oxetanyl, -NR1R2, azopentyl, phenyl, pyridyl, pyrazolyl, cyclobutyl, quinolyl, isoquinolyl, cyclopentyl, cyclohexyl, thiazolyl, furanyl, thienyl, imidazolyl, pyrimidinyl, oxoindolyl, oxotetrahydroisoquinolyl, indolyl, oxotetrahydroquinolyl.

[0059] In certain embodiments, Y1 is selected from the following structures:

[0060]

[0061] In certain embodiments, Y1 is selected from the following structures:

[0062]

[0063] In certain embodiments, Y1 is selected from phenyl, pyridyl or pyrazolyl.

[0064] In certain specific embodiments, Y1 can be substituted by any group selected from halogen, cyano, C1-C6 alkoxy, -NHCOR1, amino, hydroxyl, -NR1R2, C1-C6 alkyl, cyano, halogen, C1-C6 alkoxy, -NR1COR2, NHCOR1, C2-C6 alkynyl or C2-C6 alkenyl.

[0065] In certain embodiments, Y1 may be substituted by any group selected from halogen, cyano, C1-C3 alkyl, ethynyl, -NHCOCH3, C1-C3 alkoxy, -NCH3COCH3.

[0066] In certain embodiments, Y1 may be substituted by any substituent selected from F, Cl, Br, cyano, methyl, ethyl, ethynyl, -NHCOCH3, methoxy, -NCH3COCH3.

[0067] In certain embodiments, Y2 is methyl, ethyl, propyl, isopropyl, tert-butyl, -NHCO(CH3)2, -CONHCH3, -NHCOCH2C(CH3)3, or -N(CH3)2.

[0068] In certain specific embodiments, Y3 is selected from 3-6 membered cycloalkyl, 4-6 membered monoheterocycloalkyl, 7-10 membered heterocycloalkyl, 5-6 membered heteroaryl, phenyl, 5-6 membered aryl and 5-6 membered heterocyclyl.

[0069] In certain embodiments, Y3 is selected from 3-10 membered cycloalkyl or heterocycloalkyl. In certain specific embodiments, Y3 is a monocyclic ring or a fused bicyclic ring.

[0070] In some embodiments, Y3 is selected from 5-13 membered aryl or heteroaryl, and the aryl or heteroaryl can be monocyclic or polycyclic, and at least part of the polycyclic has aromaticity. In some specific embodiments, Y3 is monocyclic, fused bicyclic or fused tricyclic.

[0071] The number of heteroatoms in the heterocycloalkyl or heteroaryl is 1-3, and each is independently selected from N, O or S.

[0072] In certain embodiments, Y3 is selected from tetrahydropyrrolyl, tetrahydropyridinyl, tetrahydropyrazinyl, phenyl, pyridinyl, piperidinyl, piperazinyl, benzopyrrolyl.

[0073] In certain embodiments, Y3 is selected from the following structures:

[0074]

[0075] In certain embodiments, Y3 may be substituted at any possible position by one or more groups selected from fluorine, chlorine, bromine, iodine, cyano, carboxyl, methyl, ethyl, propyl, isopropyl, tert-butyl, cyclohexyl, methoxy, trifluoromethyl, CH3CO-, phenyl or pyridyl.

[0076] The present application provides a compound described in the following structure, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof, wherein the compound is selected from:

[0077]

[0078]

[0079]

[0080]

[0081]

[0082]

[0083] The present application also provides a pharmaceutical composition, which comprises a compound shown in Formula I, II, III or IV, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof.

[0084] In certain embodiments, the pharmaceutical compositions provided herein comprise a compound shown in Formula I, II, III or IV, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof, and a pharmaceutically acceptable excipient and / or carrier.

[0085] The present application also provides a compound shown in Formula I, II, III or IV, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture or pharmaceutical composition thereof, for use in preparing a drug for preventing or treating diseases related to the interaction with Menin-MLL protein.

[0086] The present application also provides the use of the aforementioned compound, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof for the preparation of a drug for preventing or treating diseases related to the interaction with Menin-MLL protein. The diseases related to the interaction with Menin-MLL protein include leukemia, leukemia-related complications, lymphoma, solid tumors or diabetes. The leukemia includes acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, or myelodysplastic syndrome, etc. The acute myeloid leukemia includes mixed rearrangement leukemia or nucleoside phosphatase 1 (NPM1) mutation leukemia, etc. The leukemia-related complications include leukemic meningitis, etc. The solid tumors include pancreatic cancer, colon cancer, liver cancer, glioblastoma, lung cancer, breast cancer, and prostate cancer. The lymphomas include Hodgkin's lymphoma, non-Hodgkin's lymphoma, plasma cell tumor, multiple myeloma, cutaneous T-cell lymphoma, lymphoid tumor, etc. DETAILED DESCRIPTION

[0087] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0088] Definitions and general notes:

[0089] "Substitution" means that a hydrogen atom in a molecule is replaced by another different atom or group.

[0090] "------" indicates a possible chemical bond, which may or may not exist. For example When “------” exists, it is a double bond; when “------” does not exist, it is a single bond.

[0091] Indicates the connection position of this group to other structures.

[0092] “Chemical bond” Unless otherwise specified, the chemical bond in the present application refers to a single bond.

[0093] "Oxo" refers to an oxygen atom forming a "C=O" structure with the directly adjacent carbon atom.

[0094] "Alkyl" refers to a saturated hydrocarbon group consisting only of carbon atoms and hydrogen atoms, with single bonds between carbons and between carbons and hydrogens, and the alkyl group can be straight or branched. Representative branched alkyl groups have one, two or three branches. The alkyl group may be optionally substituted with one or more substituents as defined herein. Alkyl includes, but is not limited to, methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl) and hexyl. Alkyl can also be part of other groups, which can be alkoxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, etc.

[0095] "Cycloalkyl" refers to a saturated or non-aromatic partially saturated ring having a single ring or multiple rings (fused, bridged, spiro). For example, examples of monocyclic alkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0096] "Heterocycloalkyl" refers to a saturated or non-aromatic partially saturated ring having a single ring or multiple rings (fused, bridged, spiro) containing at least one or more heteroatoms, wherein the heteroatoms refer to N, O and S, etc. It generally refers to a monovalent saturated or partially unsaturated monocyclic or polycyclic ring system of multiple ring atoms, which contains 1, 2 or 3 ring heteroatoms selected from N, O and S, and the remaining ring atoms are carbon.

[0097] "Cycloheteroalkyl" refers to a saturated ring or a non-aromatic partially saturated ring containing at least one or more heteroatoms, wherein the heteroatoms include N, O, S and the like.

[0098] "Ring connection" means that the rings are connected by sharing ring edges.

[0099] A "bridged ring" is a cyclic hydrocarbon in which any two rings share two carbon atoms that are not directly connected.

[0100] "Aryl" refers to an aromatic hydrocarbon group having multiple carbon atoms. Aryl is typically a monocyclic, bicyclic or tricyclic aromatic group having multiple carbon atoms. In addition, the term "aryl" as used herein refers to an aromatic substituent that can be a single aromatic ring or multiple aromatic rings fused together.

[0101] "Heteroaryl" is an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to N, O and S, etc. It is usually an aromatic monocyclic or bicyclic hydrocarbon containing multiple ring atoms, wherein one or more ring atoms are selected from O, N, S. Heteroaryl represents, for example, pyridyl, indolyl, quinoxalinyl, quinolyl, isoquinolyl, benzothienyl, benzofuranyl, benzothienyl, benzopyranyl, benzothiapyranyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, oxadiazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, etc.

[0102] "Alkenyl," used alone or in combination with other terms, refers to an unsaturated hydrocarbon group having one or more double bonds and having n to m carbons (n ​​is greater than m, and both are integers).

[0103] "Alkynyl," used alone or in combination with other terms, refers to an unsaturated hydrocarbon group having one or more triple bonds and having n to m carbons (n ​​is greater than m, and both are integers).

[0104] "Halogen" refers to fluorine, chlorine, bromine or iodine.

[0105] "Cyano" refers to -CN.

[0106] "Heteroatom" refers to an atom other than carbon or hydrogen. One or more heteroatoms in the heterocycle of the present application can be independently selected from O, S, and N, but are not limited thereto.

[0107] "Haloalkyl" refers to an alkyl group as defined above substituted by one or more, preferably 1-5 (e.g., 1, 2, 3, 4, or 5) halogen atoms, which may be F, Cl, Br, or I. Haloalkyl includes monohaloalkyl, dihaloalkyl, trihaloalkyl, perhaloalkyl, and the like, such as chloromethyl, dichloromethyl, difluoromethyl, dibromomethyl, trifluoromethyl, 2,2,2-trifluoroethyl, perfluoroethyl, 2,2,2-trifluoro-1,1-dichloroethyl, and the like.

[0108] "Alkoxy" refers to an -O-alkyl group.

[0109] "Amino" used alone or in combination with other terms refers to a radical of the formula -NH2.

[0110] "Hydroxy" refers to -OH.

[0111] In this article, unless otherwise stated, the term "Cm-Cn" used refers to the part modified by the term having mn carbon atoms (n is greater than m, and both are integers). For example, C1-C6 means that the part modified by it has 1-6 carbon atoms, such as 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. For example, C2-C6 alkenyl, it contains 2 to 6 carbon atoms, examples include but are not limited to vinyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, etc. For example, C2-C6 alkynyl, it contains 2 to 6 carbon atoms, examples include but are not limited to ethynyl, propynyl-1-yl, propynyl 2-yl, etc.

[0112] "mn-membered (hetero)cyclic hydrocarbon group" means that the part modified by the term has mn carbon atoms and the number of heteroatoms participating in the ring formation, and the heteroatoms can be nitrogen atoms, sulfur atoms, oxygen atoms, etc. (n is greater than m, and both are integers). For example, a 4-10-membered heterocyclic hydrocarbon group means that the number of carbon atoms and heteroatoms contained in the ring structure modified by the term is 4, 5, 6, 7, 8, 9 or 10.

[0113] "mn-membered (hetero)aryl" means that the part modified by the term has mn carbon atoms and the number of heteroatoms participating in the ring formation, and the heteroatom can be N, S, O, etc. (n is greater than m, and both are integers). For example, 6-12-membered aryl means that the modified aryl structure has 6, 7, 8, 9, 10, 11 or 12 carbon atoms; for example, 5-10-membered heteroaryl means that the modified heteroaryl structure has 6, 7, 8, 9 or 10 carbon atoms, and its heteroatom can be any N, S, O, etc.

[0114] "Member" refers to the number of skeleton atoms constituting the ring. Typical 5-membered rings include, for example, cyclopentyl, pyrrole, imidazole, thiazole, furan, and thiophene; typical 6-membered rings include, for example, cyclohexyl, pyridine, pyran, pyrazine, thiopyran, pyridazine, pyrimidine, benzene, etc. Among them, a ring containing heteroatoms in the skeleton atoms is a heterocycle; an aromatic group containing heteroatoms is a heteroaryl group; and a non-aromatic group containing heteroatoms is a heterocycloalkyl group.

[0115] "Optionally" means that the subsequently described event or circumstance can be freely chosen or not chosen.

[0116] "Hydrate" refers to an aggregate of the compound of the present invention containing one or more water molecules, including hemihydrate, monohydrate, dihydrate, trihydrate and the like.

[0117] "Isomer" means that when the compounds of the present invention contain one or more asymmetric centers, they can exist as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and single diastereomers. The compounds of the present invention may have asymmetric centers, which result in the existence of two optical isomers. The scope of the present invention includes all possible optical isomers and their mixtures. If the compounds of the present invention contain olefin double bonds, unless otherwise specified, the scope of the present invention includes cis isomers and trans isomers. The compounds of the present invention can exist in the form of tautomers (a kind of functional group isomers), which have different hydrogen attachment points through one or more double bond displacements, for example, a ketone and its enol form are keto-enol tautomers. Each tautomer and its mixture are within the scope of the present invention. Enantiomers of all compounds. Diastereomers, racemates, mesomorphs, cis-trans isomers, tautomers, geometric isomers, epimers and mixtures thereof are all within the scope of the present invention.

[0118] "Prodrug" refers to a derivative compound that can directly or indirectly provide the compound of the present invention after being applied to an individual. Particularly preferred derivative compounds or prodrugs are compounds that can improve the bioavailability of the compound of the present invention when applied to an individual (e.g., more easily absorbed into the blood), or compounds that promote the delivery of the parent compound to the site of action (e.g., lymphatic system). Unless otherwise indicated, all prodrug forms of the compounds of the present invention are within the scope of the present invention, and various prodrug forms are known in the art, for example, see T.Higuchi, V.Stella, Pro-drugs as Novel Drug Delivery Systems [J], American Chemical Society, Vol.14, 1975. In addition, the present invention also encompasses compounds of the present invention containing protecting groups. In any process of preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive groups or reactive groups on any related molecules, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved by conventional protecting groups, such as the protecting groups described in TWGreene, PGM Wuts, Protective Groups in Organic Synthesis [M], John Wiley & Sons, 2006. These protecting groups may be removed at an appropriate subsequent stage using methods known in the art.

[0119] "Pharmaceutical composition" refers to a preparation of a compound of the present invention and a medium generally accepted in the art for delivering biologically active compounds to mammals (e.g., humans). The medium includes a pharmaceutically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0120] "Pharmaceutically acceptable" refers to substances such as carriers, diluents or excipients that do not affect the biological activity or properties of the compounds of the invention, and are relatively non-toxic, i.e., the substance can be administered to an individual without causing adverse biological reactions or interacting with any component contained in the composition in an adverse manner. For example, "excipients" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant government regulatory authorities as acceptable for use by humans or livestock.

[0121] "Pharmaceutically acceptable salts" include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0122] Abbreviation

[0123] Cs2CO3 represents cesium carbonate;

[0124] DMF stands for N,N-dimethylformamide;

[0125] DCM means dichloromethane;

[0126] THF means tetrahydrofuran;

[0127] TEA means triethylamine;

[0128] TFA denotes trifluoroacetic acid;

[0129] DIPEA means N,N-diisopropylethylamine;

[0130] LiOH means lithium hydroxide;

[0131] HCl means hydrogen chloride;

[0132] POCl3 represents phosphorus oxychloride;

[0133] m-CPBA stands for meta-chloroperbenzoic acid;

[0134] HATU stands for 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate;

[0135] LiHMDS stands for lithium bis(trimethylsilyl)amide;

[0136] Dess-Martin means Dess-Martin periodinane.

[0137] The present invention also provides a method for synthesizing the above-mentioned compound. The method for synthesizing the present invention is mainly based on the preparation method reported in chemical literature or uses commercially available chemical reagents as starting materials for related synthesis. Specific embodiments

[0139] Preparation Example 1: Preparation of 4-(5,6-dimethoxypyridazin-3-yl)benzaldehyde (Compound 26C)

[0140]

[0141] Step 1: Preparation of 6-chloro-3,4-dimethoxypyridazine (Compound 26B):

[0142]

[0143] 3,4,6-trichloropyridazine (2 g, 10.90 mmol) was dissolved in methanol. The reaction system was cooled to 0°C. Sodium methoxide (2.36 g, 43.62 mmol) was slowly added in batches. After the addition was completed, the reaction system was stirred at room temperature for 16 hours. LCMS detection showed that the raw material was completely reacted. Compound 26B of Example 26 was obtained by separation and purification by chromatography column.

[0144] MS (ESI) m / z 175.0 (M+H) +

[0145] Step 2: Preparation of 4-(5,6-dimethoxypyridazin-3-yl)benzaldehyde (Compound 26C):

[0146]

[0147] 6-Chloro-3,4-dimethoxypyridazine (200 mg, 1.15 mmol) was dissolved in ethylene glycol dimethyl ether. Then 4-formylphenylboronic acid pinacol ester (399 mg, 1.72 mmol), tetrakistriphenylphosphine palladium (132 mg, 0.11 mmol) and sodium carbonate (304 mg, 2.86 mmol) were added. After the addition was completed, the reaction system was heated to 80°C and stirred for 6 hours. LCMS detection showed that the raw materials reacted completely. Compound 26C of Example 26 was obtained by separation and purification by chromatography column.

[0148] MS (ESI) m / z 245.1 (M+H) +

[0149] Preparation Example 2: Preparation of N-(4-formylphenyl)propionamide (Compound 34C)

[0150]

[0151] Step 1: Preparation of N-(4-(hydroxymethyl)phenyl)propanamide (Compound 34B):

[0152]

[0153] Methyl 4-propionamidobenzoate (430 mg, 2.07 mmol) was dissolved in ethanol. Sodium borohydride (236 mg, 6.22 mmol) was then slowly added in batches. After the addition was complete, the reaction system was stirred at room temperature for 16 hours. LCMS detection showed that the raw materials were completely reacted. The reaction solution was concentrated and separated and purified by chromatography to obtain compound 34B of Example 34.

[0154] MS (ESI) m / z 180.1 (M+H) +

[0155] Step 2: Preparation of N-(4-formylphenyl)propionamide (Compound 34C):

[0156]

[0157] N-(4-(Hydroxymethyl)phenyl)propionamide (206 mg, 1.15 mmol) was dissolved in dichloromethane. The reaction system was cooled to 0°C and Dess-Martin (488 mg, 1.15 mmol) was slowly added in batches. After the addition was completed, the reaction was stirred at room temperature for 2 hours. LCMS detection showed that the raw materials were completely reacted. Saturated sodium bicarbonate aqueous solution was slowly added to the reaction solution to quench the reaction, and the mixture was extracted with dichloromethane (50 mL*3). The organic phases were combined and concentrated to obtain compound 34C of Example 34.

[0158] Example 1: The preparation and synthesis steps of 2-((4-(5-(((1,4-trans)-4-(3,3-dimethylbutyramido)cyclohexyl))methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 1) are as follows:

[0159]

[0160]

[0161] Step 1: Preparation of N-ethyl-5-fluoro-2-hydroxy-N-isopropylbenzamide (Compound 1A)

[0162]

[0163] 5-Fluoro-2-hydroxybenzoic acid (10 g, 64.06 mmol) was dissolved in DCM (120 mL), and the solution was cooled to 0°C, and then oxalyl chloride (32.52 g, 256.24 mmol) was added. After stirring for 5 minutes, DMF (950 mg, 13.00 mmol) was slowly added dropwise to the system. After the addition was complete, the reaction system was refluxed overnight, and then concentrated to dryness under reduced pressure. Subsequently, DCM (150 mL) was added, and TEA (12.96 g, 128.12 mmol) was slowly added at 0°C, and finally DIPEA (6.70 g, 76.87 mmol) was slowly added. After the reaction was complete, the reaction solution was concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain compound 1A.

[0164] MS (ESI) m / z 226.1 (M+H) +

[0165] Step 2: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-(pyrimidin-5-yloxy)benzamide (Compound 1B)

[0166]

[0167] At room temperature, N-ethyl-5-fluoro-2-hydroxy-N-isopropylbenzamide (4.4 g, 19.53 mmol), 5-bromopyrimidine (6.21 g, 39.06 mmol) and Cs2CO3 (15.91 g, 48.83 mmol) were dissolved in DMF (30 mL), and then the temperature was raised to 135°C for overnight reaction. After the reaction was complete, the system was cooled to room temperature, water was added to quench the reaction, and the mixture was extracted with ethyl acetate three times. The organic phase was dried, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain compound 1B.

[0168] MS (ESI) m / z 304.1 (M+H) + .

[0169] Step 3: Preparation of 5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidine 1-oxide (Compound 1C)

[0170]

[0171] At 0°C, N-ethyl-5-fluoro-N-isopropyl-2-(pyrimidin-5-yloxy)benzamide (4.92 g, 16.22 mmol) was dissolved in DCM (50 mL), and then m-CPBA (5.93 g, 29.20 mmol) was added in batches. After the addition, the mixture was reacted at room temperature overnight. After the reaction was completed, a saturated sodium bisulfite solution was added to quench the reaction, and the reaction solution was concentrated. The crude product was separated and purified by silica gel column chromatography to obtain compound 1C.

[0172] MS (ESI) m / z 320.1 (M+H) +

[0173] Step 4: Preparation of 2-((4-chloropyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 1D)

[0174]

[0175] Under ice bath conditions, 5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidine 1-oxide (15.5 g, 54.37 mmol), TEA (1.38 g, 135.92 mmol) and chloroform (100 mL) were added to a 250 mL reaction bottle, and POCl3 (2.58 g, 168.55 mmol) was slowly added. After the addition, stirring was continued for 5 minutes, and then the reaction system was heated to 65 ° C to react overnight. After the reaction was completed, the reaction solution was concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain compound 1D.

[0176] MS (ESI) m / z 338.1 (M+H) +

[0177] Step 5: Preparation of tert-butyl 5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (Compound 1E)

[0178]

[0179] 2-((4-chloropyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (338 mg, 1.0 mmol) was dissolved in isopropanol (3.0 mL), followed by the addition of tert-butyl 3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate (210 mg, 1.0 mmol) and TEA (404 mg, 4.0 mmol). The reaction solution was stirred at 80°C for 4 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure, a small amount of water was added, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain compound 1E.

[0180] MS (ESI) m / z 512.3 (M+H) +

[0181] Step 6: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 1F)

[0182]

[0183] 5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (204 mg, 0.40 mmol) was dissolved in DCM (10 mL), and then TFA (3 mL) was added. After the addition, the reaction solution was stirred at room temperature for 4 hours. After the reaction was complete, the reaction solution was concentrated under reduced pressure to obtain compound 1F, which was directly used in the next step reaction.

[0184] MS (ESI) m / z 412.2 (M+H) +

[0185] Step 7: Preparation of tert-butyl ((trans-1,4)-4-((5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)cyclohexyl)carbamate (Compound 1G)

[0186]

[0187] N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (164 mg, 0.40 mmol) was dissolved in methanol (10 mL), followed by the addition of tert-butyl ((trans-1,4)-4-formylcyclohexyl)carbamate (90 mg, 0.40 mmol), acetic acid (48 mg, 0.80 mmol) and sodium acetate (205 mg, 2.5 mmol), and then stirred at room temperature for 1 hour. The reaction solution was cooled to 0°C, and then sodium triacetoxyborohydride (127 mg, 0.60 mmol) was added. After the addition, the reaction was stirred at room temperature for 2 hours. After the reaction is complete, add an appropriate amount of water to dilute, extract with DCM three times, wash the organic phase with saturated brine, dry with anhydrous sodium sulfate, filter and concentrate, and separate and purify the obtained crude product by silica gel column chromatography to obtain compound 1G. MS (ESI) m / z 623.4 (M+H) +

[0188] Step 8: Preparation of 2-((4-(5-(((trans-1,4)-4-aminocyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 1H)

[0189]

[0190] Tert-butyl ((trans-1,4)-4-((5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)cyclohexyl)carbamate (106 mg, 0.17 mmol) was dissolved in DCM (10 mL), followed by the addition of TFA (3 mL). After the addition, the reaction was stirred at room temperature for 4 hours. After the reaction was complete, the mixture was directly concentrated to obtain compound 1H, which was directly used in the next step.

[0191] MS (ESI) m / z 523.3 (M+H) +

[0192] Step 9: Preparation of 2-((4-(5-(((1,4-trans)-4-(3,3-dimethylbutyramido)cyclohexyl))methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 1)

[0193]

[0194] 2-((4-(5-(((trans-1,4)-4-aminocyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (78 mg, 0.15 mmol) was dissolved in DCM (10 mL), and then TEA (46 mg, 0.45 mmol) and 3,3-dimethylbutyryl chloride (20 mg, 0.15 mmol) were added thereto. The reaction system was reacted at room temperature for 2 hours. After the reaction was complete, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated by high pressure preparation to obtain compound 1 of Example 1.

[0195] MS (ESI) m / z 621.4 (M+H) +

[0196] 1H-NMR(400MHz,DMSO-d6)δ8.34(d,J=6.5Hz,1H),7.82(d,J=18.6Hz,1H),7.5 5(d,J=7.9Hz,1H),7.25(m,2H),6.97(m,1H),4.33(dd,J=42.9,9.9Hz,4H),3. 85–3.66(m,1H),3.42(s,5H),3.28–3.09(m,2H),2.47(d,J=7.0Hz,2H),1.90( s,2H),1.78(t,J=13.7Hz,4H),1.08(m,13H),0.94(s,9H),0.91–0.86(m,1H).

[0197] Example 2: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-(((trans-1,4)-4-(3,3-dimethylureido)cyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 2)

[0198]

[0199] 2-((4-(5-(((trans-1,4)-4-aminocyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (88 mg, 0.17 mmol) was dissolved in THF (10 mL), and then TEA (34 mg, 0.34 mmol) and dimethylaminoformyl chloride (54 mg, 0.51 mmol) were added in sequence. After the addition, the reaction system was reacted at room temperature for 16 hours. After the reaction was complete, a small amount of water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated by high pressure preparation to obtain compound 2 of Example 2.

[0200] MS (ESI) m / z 594.3 (M+H) +

[0201] 1H-NMR(400MHz,DMSO-d6)δ8.34(d,J=6.4Hz,1H),7.82(d,J=18.3Hz,1H),7.33–7 .15(m,2H),6.98(m,1H),5.85(d,J=7.8Hz,1H),4.33(dd,J=42.9,10.5Hz,4H),3. 78(p,J=6.7Hz,1H),3.42(s,5H),3.30–3.05(m,2H),2.75(s,6H),2.47(d,J=7.0H z,2H),1.78(t,J=13.4Hz,4H),1.23–0.98(m,12H),0.88(q,J=12.0,11.5Hz,2H).

[0202] Example 3: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-((tetrahydro-2H-pyran-4-yl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 3):

[0203]

[0204]

[0205] N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (188 mg, 0.46 mmol) was dissolved in methanol, followed by the addition of acetic acid (55 mg, 0.91 mmol), sodium acetate (187 mg, 2.28 mmol) and tetrahydropyran-4-carbaldehyde (78 mg, 0.69 mmol). After the addition, the reaction was stirred at room temperature for 1 hour, and then sodium triacetoxyborohydride (194 mg, 0.91 mmol) was added in batches. After the addition, the reaction system was stirred at room temperature for 1 hour. After the reaction was complete, an appropriate amount of water was added for dilution, and DCM was extracted 3 times. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the obtained crude product was purified by high pressure preparative separation to obtain compound 3 of Example 3.

[0206] MS (ESI) m / z 510.3 (M+H) +

[0207] 1H NMR (400MHz, DMSO-d6) δ8.34(d,J=6.5Hz,1H),7.82(d,J=18.3Hz,1H),7.25(m,2H),6.97(m,1H),4.33(dd,J=41.3,10 .0Hz,4H),3.87–3.72(m,3H),3.50–3.36(m,5H),3.31–3.10(m,4H),1.62(dd,J=9.5,5.9Hz,3H),1.25–0.97(m,12H).

[0208] Using compound 1F as the reaction substrate and the commercial or homemade reagents shown in the table as raw materials, Examples 4-9 were prepared by referring to the synthesis method of Example 3. The specific information is shown in the following table.

[0209]

[0210]

[0211] The characterization data of the compounds in Examples 4-9 are shown in the following table.

[0212]

[0213]

[0214] Example 10: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-(4-(5-((4-(methylcarbamoyl)cyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 10):

[0215]

[0216] Step 1: Preparation of methyl 4-((5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)cyclohexane-1-carboxylate (Compound 10A)

[0217]

[0218] N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (1.0 g, 2.43 mmol) was dissolved in methanol (25.0 mL), followed by the addition of sodium acetate (1.01 g, 12.15 mmol), acetic acid (0.29 g, 4.86 mmol) and methyl 4-formylcyclohexane-1-carboxylate (0.41 g, 2.43 mmol), the reaction solution was stirred at room temperature for 1 hour, then the reaction solution was cooled to 0°C, and sodium triacetoxyborohydride (1.03 g, 4.86 mmol) was added thereto. After the reaction was complete, water was added to quench the reaction, the mixture was extracted with ethyl acetate, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated and purified by silica gel column chromatography to obtain compound 10A in Example 10.

[0219] MS (ESI) m / z 566.3 (M+H) +

[0220] Step 2: Preparation of 4-((5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)cyclohexane-1-carboxylic acid (Compound 10B)

[0221]

[0222] At room temperature, 4-((5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)cyclohexane-1-carboxylic acid methyl ester (500 mg, 0.88 mmol) was dissolved in methanol (10 mL), and then 2N lithium hydroxide aqueous solution (2 mL) was added thereto, and the mixture was reacted at room temperature for 2 hours. After the reaction was complete, the reaction solution was adjusted to neutral with 1N hydrochloric acid, and then the solvent was directly spin-dried to obtain compound 10B in Example 10.

[0223] MS (ESI) m / z 552.3 (M+H) + .

[0224] Step 3: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-(4-(5-((4-(methylcarbamoyl)cyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 10):

[0225]

[0226] 4-((5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)cyclohexane-1-carboxylic acid (200 mg, 0.49 mmol) was dissolved in DMF (20 mL), and then DIPEA (190 mg, 1.47 mmol), methylamine (15 mg, 0.49 mmol), and HATU (370 mg, 0.98 mmol) were added thereto, and the mixture was reacted at room temperature for 8 hours. After the reaction was complete, water was added to quench the reaction, the reaction solution was extracted with dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and the crude product was separated by high pressure preparation to obtain compound 10 of Example 10.

[0227] MS (ESI) m / z 565.3 (M+H) +

[0228] 1 H NMR (400MHz, DMSO-d6) δ8.34 (dd, J=6.5, 1.8Hz, 1H), 7.82 (dd, J=18.7, 1.6Hz, 1H), 7.60 (q, J=5.2 ,4.7Hz,1H),7.35–7.14(m,2H),7.06–6.88(m,1H),4.33(dd,J=42.6,9.6Hz,4H),3.84–3.73(m,1 H),3.41(s,5H),3.18(m,1H),2.53(m,3H),2.46(d,J=7.0Hz,2H),2.01(t,J=12.0Hz,1H),1.82(d ,J=13.0Hz,2H),1.73–1.61(m,2H),1.44–1.27(m,3H),1.20–1.00(m,9H),0.83(q,J=12.6Hz,2H).

[0229] Example 11: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-(((trans-1,4)-4-((N,N-dimethylsulfamoyl)amino)cyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 11):

[0230]

[0231] 2-((4-(5-(((trans-1,4)-4-aminocyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (88 mg, 0.17 mmol) was dissolved in THF (10 mL), and then TEA (34 mg, 0.34 mmol) and dimethylaminosulfonyl chloride (72 mg, 0.51 mmol) were added thereto. The reaction system was reacted at room temperature for 16 hours. After the reaction was complete, a small amount of water was added to quench the reaction, and then extracted with ethyl acetate, the organic phases were combined, dried over anhydrous sodium sulfate, filtered and concentrated, and the obtained crude product was purified by high pressure preparative separation to obtain compound 11 of Example 11.

[0232] MS (ESI) m / z 630.3 (M+H) +

[0233] 1 H NMR(400MHz,DMSO-d6)δ8.34(d,J=6.5Hz,1H),7.82(d,J=18.5Hz,1H),7.26(m,2H), 7.10(d,J=7.9Hz,1H),6.97(m,1H),4.45–4.18(m,4H),3.86–3.69(m,1H),3.41(s,5H) ),3.27–3.13(m,1H),2.98–2.87(m,1H),2.62(s,6H),2.44(d,J=7.0Hz,2H),1.84(dd ,J=39.4,12.3Hz,4H),1.31–1.15(m,4H),1.13–0.93(m,8H),0.87(q,J=12.1Hz,2H).

[0234] Using compound 1H as the reaction substrate and the commercial or homemade reagents shown in the table as raw materials, Examples 12-13 were prepared by referring to the synthesis method of Example 11. The specific information is shown in the following table.

[0235]

[0236] The characterization data of the compounds in Examples 12-13 are shown in the following table.

[0237]

[0238]

[0239] Example 14: Preparation of N-ethyl-2-((4-(5-(((trans-1,4)-4-(ethylsulfonamido)cyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide (Compound 14):

[0240]

[0241] 2-((4-(5-(((trans-1,4)-4-aminocyclohexyl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (88 mg, 0.17 mmol) was dissolved in DCM (10 mL), and TEA (38 mg, 0.38 mmol) and ethylsulfonyl chloride (28 mg, 0.23 mmol) were then added thereto. After the addition, the reaction system was reacted at room temperature for 2 hours. After the reaction was complete, a small amount of water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the obtained crude product was purified by high pressure preparative separation to obtain compound 14 of Example 14.

[0242] MS (ESI) m / z 614.3 (M+H) +

[0243] 1 H NMR (400MHz, DMSO-d6) δ8.34(d,J=6.4Hz,1H),7.82(d,J=18.4Hz,1H),7.36–7.14(m,2H),7.06–6.83(m,2H),4.33(dd,J=42.9,9.9Hz,4H),3.78( q,J=6.6Hz,1H),3.41(s,4H),3.30–3.07(m,2H),2.97(t,J=7.4Hz,3H),2 .45(d,J=7.1Hz,2H),1.83(dd,J=28.3,12.7Hz,4H),1.35–0.82(m,17H).

[0244] Using compound 1H as the reaction substrate and the commercial or homemade reagents shown in the table as raw materials, Examples 15-21 were prepared by referring to the synthesis method of Example 14. The specific information is shown in the following table.

[0245]

[0246]

[0247] The characterization data of the compounds in Examples 15-21 are shown in the following table.

[0248]

[0249]

[0250] Example 22: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-((1S,3aR,6aS)-octahydrocyclopentyl[c]pyrrole-1-carbonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 22):

[0251]

[0252]

[0253] Step 1: Preparation of (1S,3aR,6aS)-1-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (Compound 22A)

[0254]

[0255] N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (99 mg, 0.24 mmol) was dissolved in DMF. Then, (1S,3aR,6aS)-hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylic acid 2-tert-butyl ester (61 mg, 0.24 mmol), HATU (183 mg, 0.48 mmol) and N,N-diisopropylethylamine (124 mg, 0.96 mmol) were added in sequence. After the addition was completed, the reaction was stirred at room temperature for 1 hour. LCMS detection showed that the raw materials were completely reacted. The obtained crude product was separated and purified by high pressure preparative separation to obtain Compound 22A of Example 22.

[0256] MS (ESI) m / z 649.3 (M+H) +

[0257] Step 2: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-((1S,3aR,6aS)-octahydrocyclopentyl[c]pyrrole-1-carbonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 22)

[0258]

[0259] (1S,3aR,6aS)-1-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1,2,3,4,5,6-hexahydropyrrolo[3,4-c]pyrrole-2-carbonyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylic acid tert-butyl ester (120 mg, 0.18 mmol) was dissolved in a dichloromethane solution. Trifluoroacetic acid (2 mL) was added. After the addition was completed, the reaction system was stirred at room temperature for 30 minutes. LCMS detection showed that the raw materials reacted completely. After the reaction solution was concentrated, sodium carbonate aqueous solution was added to adjust the pH to 9, and the solution was extracted with dichloromethane (50 mL*3). After the organic phases were combined and concentrated, the resulting crude product was subjected to high pressure preparative separation and purification to obtain compound 22 of Example 22.

[0260] MS (ESI) m / z 549.3 (M+H)+

[0261] 1 H NMR(400MHz,DMSO-d6)δ8.36(d,J=7.4Hz,1H),7.83(d,J=21.1Hz,1H),7.27(m, 2H),7.02(m,1H),4.63–4.27(m,7H),4.23–4.03(m,2H),3.79(m,1H),3.36(d,J= 4.4Hz,2H),3.20–3.07(m,2H),2.58(m,1H),2.35(dd,J=10.8,5.5Hz,1H),1.81 –1.68(m,1H),1.68–1.55(m,2H),1.48(m,2H),1.32(m,1H),1.25–0.96(m,10H).

[0262] Using compound 1F as a reaction substrate and the commercial or homemade reagents shown in the table as raw materials, Examples 23-24, 27-33, 36-44 were prepared by referring to the synthesis method of Example 22. Using compound 1F as a reaction substrate and the commercial or homemade reagents shown in the table as raw materials, Examples 25-26 and 34-35 were prepared by referring to the synthesis method of Example 3. The specific situation is shown in the following table.

[0263]

[0264]

[0265]

[0266]

[0267]

[0268] The characterization data of the compounds in Examples 23-44 are shown in the following table.

[0269]

[0270]

[0271]

[0272]

[0273] Example 45: Preparation of (S)-2-((4-(5-(2-amino-2-methyl-3-phenylpropionyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 45):

[0274]

[0275] Step 1: Preparation of (9H-fluoren-9-yl)methyl (S)-(1-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-methyl-1-oxo-3-phenylpropan-2-yl)carbamate (Compound 45A):

[0276]

[0277] N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (39 mg, 0.095 mmol), (S)-2-((((9H-fluorene-9-yl)methoxy)carbonyl)amino)-2-methyl-3-phenylpropionic acid (25 mg, 0.095 mmol), HATU (54 g, 0.14 mmol) and DMF (3.0 mL) were added to the reaction bottle, and N,N-diisopropylethylamine (37 mg, 0.29 mmol) was slowly added. After the addition was completed, the reaction was allowed to react at room temperature for 3 hours. After the reaction was complete, the compound 45A of Example 45 was obtained by separation and purification by high-performance liquid phase.

[0278] MS (ESI) m / z 795.4 (M+H) +

[0279] Step 2: Preparation of (S)-2-((4-(5-(2-amino-2-methyl-3-phenylpropionyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 45):

[0280]

[0281] (9H-fluoren-9-yl)methyl (S)-(1-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-2-methyl-1-oxo-3-phenylpropan-2-yl)carbamate (17 mg, 0.021 mmol), diethylamine (31 mg, 0.27 mmol) and acetonitrile (10.0 mL) were added to the reaction bottle. After the addition was completed, the reaction was allowed to react at room temperature for 3 hours. After the reaction was complete, the compound 45 of Example 45 was obtained by separation and purification by high performance liquid phase.

[0282] MS (ESI) m / z 573.3 (M+H) +

[0283] 1 H NMR (400MHz, DMSO-d6) δ8.36(d,J=7.5Hz,1H),7.83(d,J=21.9Hz,1H),7.33–7.22(m,4H),7.17(t,J=8.8Hz,3H),7.05–6.93(m,1H),4.68–4 .07(m,9H),3.40(m,1H),3.24(m,1H),2.97(d,J=13.0Hz,1H),2.80(d,J=13.0Hz,1H),1.77(s,2H),1.24(s,3H),1.18(s,1H),1.06(m,8H).

[0284] Using compound 1F as the reaction substrate and the commercial or homemade reagents shown in the table as raw materials, referring to the synthesis method of Example 22, Examples 46-69 were prepared.

[0285]

[0286]

[0287]

[0288]

[0289]

[0290] The characterization data of the compounds in Examples 15-21 are shown in the following table.

[0291]

[0292]

[0293]

[0294]

[0295]

[0296] Example 70: Preparation of (S)-4-(2-amino-3-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-oxypropyl)benzoic acid (Compound 70):

[0297]

[0298] Step 1: Preparation of (S)-tert-butyl 4-(2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-oxopropyl)benzoate (Compound 70A):

[0299]

[0300] N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (0.08 g, 0.19 mmol) was dissolved in N,N-dimethylformamide solution, and then (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxycarbonyl)phenyl)propanoic acid (0.14 g, 0.29 mmol), N,N-diisopropylethylamine (0.074 g, 0.57 mmol) and HATU (0.14 g, 0.38 mmol) were added. After the addition was completed, the reaction system was stirred at room temperature for 16 hours. LCMS showed that the raw materials were reacted completely. After the reaction was complete, the mixture was separated and purified by chromatography to obtain Compound 70A of Example 70.

[0301] MS (ESI) m / z 881.2 (M+H) +

[0302] Step 2: Preparation of (S)-tert-butyl 4-(2-amino-3-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-oxopropyl)benzoate (Compound 70B):

[0303]

[0304] (S)-tert-butyl 4-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-oxopropyl)benzoate (0.115 g, 0.13 mmol) was dissolved in a dichloromethane solution, and then DBU (0.04 g, 0.26 mmol) was added. After the addition was completed, the reaction system was stirred at room temperature for 0.5 hour. After the reaction was completed, the compound 70B of Example 70 was separated and purified by chromatography. MS (ESI) m / z 659.2 (M+H) +

[0305] Step 3: Preparation of (S)-4-(2-amino-3-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-oxopropyl)benzoic acid (Compound 70):

[0306]

[0307] (S)-tert-butyl 4-(2-amino-3-(5-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-oxopropyl)benzoate (0.06 g, 0.091 mmol) was dissolved in dichloromethane solution, and trifluoroacetic acid (0.52 g, 4.55 mmol) was then added. After the addition was completed, the reaction system was stirred at room temperature for 1 hour. LCMS showed that the raw material reacted completely. The reaction solution was concentrated under reduced pressure to give a crude product, which was separated by high pressure preparation to obtain compound 70 of Example 70.

[0308] MS (ESI) m / z 603.2 (M+H) +

[0309] 1H NMR(400MHz, Methanol-d4)δ8.36–8.31(m,1H),7.94–7.84(m,3H),7.30(d,J= 7.6Hz,2H),7.22–7.14(m,2H),6.91(d,J=4.2Hz,1H),4.56–4.25(m,6H),4.22 –4.11(m,2H),3.94–3.90(m,1H),3.68(t,J=16.0Hz,1H),3.55–3.45(m,1H),3 .40(d,J=7.0Hz,1H),3.21–3.11(m,1H),3.07–3.02(m,1H),1.31–1.11(m,9H).

[0310] Example 71: Preparation of N-ethyl-5-fluoro-2-((4-(5-(3-(4-fluorophenyl)-2-methyl-2-(methylamino)propanoyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-isopropylbenzamide (Compound 71):

[0311]

[0312] Step 1: Preparation of methyl 2-((diphenylmethylene)amino)propanoate (Compound 71B):

[0313]

[0314] Dissolve methyl 2-aminopropionate (10.0 g, 96.97 mmol), diphenylmethane (17.57 g, 96.97 mmol) and triethylamine (29.44 g, 290.91 mmol) in dichloromethane (100.0 mL). After the addition is complete, react at room temperature for 24 hours. LCMS shows that the raw materials have not reacted completely. The reaction solution is washed with water, dried over anhydrous sodium sulfate, and the crude product obtained after concentration is separated and purified by a chromatography column to obtain compound 71B of Example 71.

[0315] MS (ESI) m / z = 268.1 (M+H) + .

[0316] Step 2: Preparation of methyl 2-((diphenylmethylene)amino)-3-(4-fluorophenyl)-2-methylpropanoate (Compound 71C):

[0317]

[0318] Dissolve methyl 2-((diphenylmethylene)amino)propanoate (3.5 g, 13.09 mmol) in tetrahydrofuran (50.0 mL), replace with nitrogen five times, cool in an ice-water bath, and slowly drop LiHMDS (8.76 g, 52.36 mmol). After the addition is complete, react at 0°C for 1 hour. Add 1-(bromomethyl)-4-fluorobenzene (7.42 g, 39.27 mmol) to the reaction system. After the addition is complete, the reaction system is stirred at room temperature for 1 hour. LCMS shows that the raw material reacts completely. The reaction solution is quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product separated and purified by a chromatography column to obtain compound 71C of Example 71. MS (ESI) m / z = 376.2 (M+H) + .

[0319] Step 3: Preparation of methyl 2-amino-3-(4-fluorophenyl)-2-methylpropanoate (Compound 71D):

[0320]

[0321] Dissolve methyl 2-((diphenylmethylene)amino)-3-(4-fluorophenyl)-2-methylpropanoate (2.0 g, 7.48 mmol) in 1,4-dioxane (40.0 mL) and 3N hydrochloric acid (20.0 mL). After the addition is complete, react at room temperature for 2 hours. LCMS shows that the raw material is completely reacted. The crude product after direct concentration of the reaction solution is purified by high-performance liquid separation to obtain compound 71D of Example 71. MS (ESI) m / z = 212.1 (M+H) + .

[0322] Step 4: Preparation of methyl 2-((tert-butoxycarbonyl)amino)-3-(4-fluorophenyl)-2-methylpropanoate (Compound 71E):

[0323]

[0324] Dissolve methyl 2-amino-3-(4-fluorophenyl)-2-methylpropanoate (1.5 g, 5.53 mmol) in ethanol (20.0 mL), and add di-tert-butyl dicarbonate (1.44 g, 6.63 mmol) to the reaction system. After the addition is complete, react at room temperature for 15 hours. After the reaction is complete, concentrate the reaction solution to obtain a crude product, separate and purify it by chromatography to obtain Compound 71E of Example 71.

[0325] MS (ESI) m / z = 212.1 (M + H-100) + .

[0326] Step 5: Preparation of methyl 2-((tert-butoxycarbonyl)(methyl)amino)-3(4-fluorophenyl)-2-methylpropanoate (Compound 71F):

[0327]

[0328] Dissolve methyl 2-((tert-butyloxycarbonyl)amino)-3-(4-fluorophenyl)-2-methylpropanoate (1.3 g, 4.18 mmol) in DMF (35.0 mL) and replace with nitrogen three times. Add sodium hydride (1.40 g, 58.52 mmol) all at once and react at room temperature for 0.5 hours. Add iodomethane (14.24 g, 100.32 mmol) to the reaction system. Add and react at room temperature for 5 hours. LCMS shows that the raw material is basically reacted. The reaction solution is quenched with water, extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product separated and purified by a chromatography column to obtain compound 71F of Example 71.

[0329] MS(ESI)m / z=226.1(M+H-100)+.

[0330] Step 6: Preparation of 3-(4-fluorophenyl)-2-methyl-2-(methylamino)propanoic acid (Compound 71G):

[0331]

[0332] Dissolve methyl 2-((tert-butyloxycarbonyl)(methyl)amino)-3(4-fluorophenyl)-2-methylpropanoate (1 g, 3.07 mmol) in ethanol (40.0 mL). Dissolve sodium hydroxide (1.23 g, 30.7 mmol) in water (10.0 mL) and add them to the reaction system. After the addition is complete, the reaction temperature is raised to 80°C for 18 hours. LCMS shows that a small amount of raw materials are unreacted. The reaction solution is cooled to room temperature, the pH is adjusted to 4, and the crude product obtained by concentration is separated and purified by chromatography to obtain compound 71G of Example 71.

[0333] MS (ESI) m / z = 212.1 (M+H)+.

[0334] Step 7: Preparation of N-ethyl-5-fluoro-2-((4-(5-(3-(4-fluorophenyl)-2-methyl-2-(methylamino)propanoyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-isopropylbenzamide (Compound 71):

[0335]

[0336] 3-(4-fluorophenyl)-2-methyl-2-(methylamino)propionic acid was used to replace (1S,3aR,6aS)-hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylic acid 2-tert-butyl ester in Example 22, and the same preparation method as Example 22 was used to obtain Compound 71 of Example 71. MS (ESI) m / z 605.3 (M+H) +

[0337] 1 H NMR(400MHz, DMSO-d6)δ8.37(d,J=7.5Hz,1H),7.27(m,2H),7.17–7.10(m,2H),7. 06(t,J=8.8Hz,2H),6.97(dd,J=8.1,4.3Hz,1H),4.67–4.10(m,9H),3.80(m,1H), 3.40(dd,J=13.6,6.9Hz,1H),3.28–3.16(m,1H),2.98(d,J=13.8Hz,1H),2.80(d, J=13.4Hz,1H),2.17(d,J=5.9Hz,3H),1.81(q,J=6.0Hz,1H),1.17–1.00(m,12H).

[0338] Example 72: Preparation of 2-((4-(5-((1-acetylpiperidin-4-yl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 72):

[0339]

[0340] Step 1: Preparation of tert-butyl 4-((5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)methyl)piperidine-1-carboxylate (Compound 72A):

[0341]

[0342] To a solution of N-ethyl-5-fluoro-N-isopropyl-2-((4-(3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (0.14 g, 0.34 mmol) in methanol (10 mL) was added tert-butyl 4-formylpiperidine-1-carboxylate (0.087 g, 0.41 mmol) and sodium triacetoxyborohydride (0.14 g, 0.68 mmol) at room temperature. The mixture was reacted at room temperature for 30 minutes. After the reaction was complete, water was added to quench the reaction, and the mixture was concentrated under reduced pressure. The mixture was then extracted with ethyl acetate. The organic phase was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain Compound 72A of Example 72.

[0343] MS (ESI) m / z 609.4 [M+H] +

[0344] Step 2: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-(piperidin-4-ylmethyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (Compound 72B):

[0345]

[0346] Trifluoroacetic acid was added to a dichloromethane solution of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-(piperidin-4-ylmethyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (195 mg, 0.32 mmol) at room temperature, followed by reaction at room temperature for 1 hour. After the reaction was complete, the crude product was concentrated and separated by high pressure preparation to obtain Compound 72B of Example 72. MS (ESI) m / z 509.3 [M+H] +

[0347] Step 3: Preparation of 2-((4-(5-((1-acetylpiperidin-4-yl)methyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (Compound 72):

[0348]

[0349] To a dichloromethane solution of N-ethyl-5-fluoro-N-isopropyl-2-((4-(5-(piperidin-4-ylmethyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)pyrimidin-5-yl)oxy)benzamide (90 mg, 0.32 mmol) was added acetic anhydride (55.13 mg, 0.54 mmol) and triethylamine (72.86 mg, 0.72 mmol) at room temperature. The mixture was reacted at room temperature for 30 minutes. After the reaction was complete, the crude product was concentrated and isolated by high pressure preparation to obtain Compound 72 of Example 72.

[0350] MS (ESI) m / z 551.3 [M+H] +

[0351] 1 H NMR (400MHz, Methanol-d4) δ8.33(d,J=5.7Hz,1H),7.85(d,J=13.8Hz,1H),7.18(m,2H),6.96–6.89(m,1H),4.59–4.32(m,5H),3.92(dd,J=13.2,6.3Hz,2 H),3.60–3.45(m,5H),3.41–3.32(m,2H),3.17–3.06(m,1H),2.69–2.58(m,3 H),2.08(s,3H),1.95–1.71(m,3H),1.30(d,J=6.8Hz,1H),1.25–1.08(m,9H).

[0352] Experimental Example 1: Menin-MLL protein interaction inhibitory activity test

[0353] Fluorescence Polarization method was used to detect the IC of the test compound inhibiting the Menin-MLL protein interaction 50 value.

[0354] The specific steps are as follows: the compound stock solution (10 mM, DMSO preparation) is diluted with DMSO to 2000, 600, 200, 60, 20, 6, 2, 0.6, 0.2, 0.06 μM. 50 nL of different concentrations of the test compound (10 gradient concentrations) and DMSO solution without the compound (negative control well) are taken by ECHO 665 Series Acoustic Liquid Handlers (BECKMAN Inc.), transferred to a 384-well plate, and centrifuged at 1000 rpm for use. 5 μL of Menin (BIORTUS Inc., Cat No. BP9210) is added to each assay well using I.DOT (DISPENDIX Inc.) and incubated at 25°C for 10 minutes. 5 μL of FITC-MLL4-43 (Genscrip Inc.) is added to each assay well using I.DOT, centrifuged at 1000 rpm and incubated for 60 minutes. The FP signal was measured and the data were processed using a PHERAstar FSX multifunctional microplate reader (BMG Labtech Inc.).

[0355] Fitting compound IC with nonlinear regression equation 50 :Inhibition%=(negative control well signal-compound well signal) / (negative control well signal-background signal)*100% (background signal is the signal value detected in the assay well containing only 5μL FITC-MLL4-43), with the log value of compound concentration as the X-axis and the percentage inhibition rate (Inhibition%) as the Y-axis, the dose-effect curve was fitted to obtain the IC value of each compound for inhibiting the Menin-MLL protein interaction. 50 The experimental results are shown in Table 1 below:

[0356] Table 1 IC of the compounds of the present invention for inhibiting Menin-MLL protein interaction 50 value

[0357]

[0358]

[0359] Note: “-” means not tested.

[0360] Conclusion: The above experiments show that the compounds of the present invention have excellent activity in inhibiting the Menin-MLL protein interaction.

[0361] Experimental Example 2: Cell proliferation inhibition experiment (MV-4-11, MOLM-13, HL60 cells)

[0362] Cell plating:

[0363] 1) Take the cells out of the incubator and place them on the workbench. Mix them by gently pipetting and count them using CounterStar.

[0364] 2) Dilute the cells to the required density with fresh complete medium. MV-4-11 (cell source: Nanjing Kebai, catalog number: CBP60522), culture medium: IMDM (HyClone, catalog number: SH30228.01) + 20% FBS (Excell Bio, catalog number: FSP500) + 1% P / S (HyClone, catalog number: SV30010), the plating density is 1×10^4 cells / well, 100μL / well; MOLM-13 (cell source is Nanjing Kebai, catalog number CBP60678) culture medium is RPMI1640 (GIBCO, catalog number: C11875500BT) + 10% FBS + 1% P / S, the plating density is 1×10^3 cells / well, 100μL / well; HL-60 (cell source is Nanjing Kebai, catalog number CBP60517), the culture medium is IMDM + 10% FBS + 1% P / S, the plating density is 1×10^4 cells / well, 100μL / well.

[0365] 3) Use an electric dispenser to pipette 100 μL of each of the above cell suspensions into a 96-well plate.

[0366] Formulated compound:

[0367] 1) First, the stock solution of the compound was diluted with DMSO from 10 mM to 2000, 600, 200, 60, 20, 6, 2, 0.6, and 0 μM, with 0 μM as the control well.

[0368] 2) After thorough mixing, 2.6 μL was taken out with an electric ejector and added to 257.4 μL of culture medium. At this time, the solution was diluted 100 times and the DMSO content was 1%.

[0369] 3) After thoroughly mixing with a shotgun, take out the cells, set up two replicate wells for each concentration of each compound, add 100 μL of the compound diluted in step 2 to each of the two replicate wells, and the final concentrations of the compounds are: 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0 μM. At this time, each well of the cell culture plate contains 200 μL of culture medium, and the DMSO content is 0.5%, of which the well containing only 0.5% DMSO (compound concentration is 0) is the control well.

[0370] 4) The cells were returned to the 37° C., 5% CO 2 incubator for continued culture. MV-4-11 cells were tested 3 days after the addition of the compound, and MOLM-13 and HL-60 cells were tested 5 days after the addition of the compound.

[0371] CTG test:

[0372] 1) After culturing for a specific period of time, remove the cells and aspirate a portion of the culture medium to leave 50 μL of culture medium in each well, and add 50 μL / well of CTG reagent (cell counting-Lite 2.0, Vazyme, DD1101-02) using a dispenser.

[0373] 2) Incubate on a shaker at room temperature for 15 min, and then allow to equilibrate at room temperature for 15 min.

[0374] 3) Detection using a multifunctional microplate reader.

[0375] Data Analysis:

[0376] 1) Calculate the cell viability, Cell viability % = As / Ac×100%. As: test well (culture medium containing cells, CTG, test compound), Ac: control well (culture medium containing cells, CTG, no test compound).

[0377] 2) Using the log value of the compound concentration as the X-axis and the cell viability (Cell viability%) as the Y-axis, the dose-effect curve was fitted to obtain the IC value of each compound on the cell proliferation inhibition activity. 50 value.

[0378] Table 2 Proliferation inhibition activity of the compounds of the present invention on MV-4-11 / MOLM-13 / HL-60 cells

[0379]

[0380]

[0381] Note: “-” in Table 2 means that it has not been tested yet.

[0382] The test results show that the compound of the present application has good activity on MLL-r-carrying cells MV-4-11 / MOLM-13; the activity on MLL-WT cells HL-60 is significantly poorer, which to some extent indicates that the compound has a selective inhibitory effect on MLL-r cells.

[0383] Example 3: Cardiac safety test of drugs related to hERG potassium channel

[0384] The IC of the test compound on hERG potassium channel inhibition was determined by fluorescence polarization method. 50 value.

[0385] Reagent information: Predictor TM hERG Fluorescence Polarization Assay Kit (Cat. No.: PV5365)

[0386] The specific steps are as follows: the test compound and E-4031 (positive reference compound) are prepared with DMSO to a 20× series concentration, and then the Assay buffer (Predictor TM hERG Fluorescence Polarization Assay Kit) was diluted to a 4× series of concentrations. The starting concentration of the test compound was 100μM, and the starting concentration of E-4031 was 30μM. Take 2.5μL of 6 different concentrations of the test compound solution or 8 different concentrations of E-4031 solution, add them to a 384-well plate, and add 2.5μL Assay buffer to the negative control well. Add 5μL of hERG Membrane solution to each well; 2.5μL of hERG Tracer Red solution (diluted with Assay buffer to a final concentration of 4nM). Incubate at room temperature in the dark for 4h, and use a multifunctional microplate reader with a polarization optical element of 540 / 20-590 / 20nm to measure the fluorescence polarization value of each well.

[0387] The hERG inhibition IC50 value was obtained by performing nonlinear regression (dose response-variable slope) fitting with the log value of compound concentration as the X-axis and the fluorescence polarization value as the Y-axis.

[0388] Table 3 IC inhibition of hERG by compounds of the present invention 50 value

[0389]

[0390]

Claims

1. A compound of formula I, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof: Wherein R is -LX; n = 0 or 1; When n=1, L is selected from C1-C6 alkyl, 3-7 membered monocycloalkyl, 6-10 membered cycloalkyl, 6-10 membered bridged cycloalkyl, 6-10 membered cycloheteroalkyl, 3-7 membered heterocycloalkyl, 6-14 membered aryl, 5-12 membered heteroaryl; optionally, the 6-14 membered aryl or 5-12 membered heteroaryl is replaced by one or more selected from C1-C3 alkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, C1-C3 haloalkyl, cyano, halogen, -NHCORo, R y CO-、-(CH2)mCONR p R q substituted by a group, m=0 or 1 or 2; wherein, R o Selected from C1-C6 alkyl, 3-6 membered cycloalkyl or heterocycloalkyl or -N(CH3)2; R y is selected from C1-C6 alkyl, 5-7 membered aryl or heteroaryl; R p , R q Each independently selected from H or C1-C3 alkyl; X is selected from -NHSO2Y1, -NHCOY2 or absent; Wherein Y1 is selected from C1-C6 alkyl, 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, -NR1R2, 6-14 membered aryl, 5-12 membered heteroaryl; wherein when Y1 is selected from 3-7 membered cycloalkyl or 3-7 membered heterocycloalkyl, each is optionally substituted by one or more groups selected from C1-C6 alkyl, halogen, cyano, C1-C6 alkoxy, -NRvCOR1, amino, hydroxyl or -NR1R2; wherein when Y1 is selected from 6-14 membered aryl or 5-12 membered heteroaryl, each is optionally substituted by one or more Rx groups, the Rx groups are selected from C1-C6 alkyl, cyano, halogen, C1-C6 alkoxy, -NR1COR2, C2-C6 alkynyl, amino, hydroxyl, -NR1R2 or C2-C6 alkenyl substituted groups, or the Rx groups form a 9-10 membered cyclic ring with Y1; Rv is selected from H or C1-C3 alkyl; Wherein Y2 is selected from C1-C6 alkyl or NR1R2; R1 or R2 are each independently selected from H or C1-C3 alkyl; When n=0, L represents a chemical bond, X is -COY3; Alternatively, L represents a chemical bond and X is where a is 0, 1 or 2, R3 is C1-C3 alkyl, R3 may be substituted by one or more R5 at any possible position, R5 may be independently selected from halogen, cyano, hydroxyl, amino, carboxyl; Alternatively, R3 is selected from NR6R7, and R6 and R7 may be independently selected from H, C1-C3 alkyl, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl; R4 is selected from H or C1-C3 alkyl; wherein Y3 is selected from 3-7 membered cycloalkyl, 4-10 membered heterocycloalkyl, 5-8 membered aryl, 5-8 membered heteroaryl, 5-7 membered aryl and 5-7 membered heterocyclyl; Alternatively, Y3 is selected from 3-12 membered cycloalkyl or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl may be monocyclic or polycyclic; Alternatively, Y3 is selected from a 5-16 membered aryl or heteroaryl group, wherein the aryl or heteroaryl group may be monocyclic or polycyclic, and at least part of the polycyclic rings are aromatic; Optionally, Y3 is further substituted by one or more selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl, 5-8 membered aryl, 5-7 membered heteroaryl, halogen, cyano, amino, carboxyl, carboxyl, C1-C6 alkoxy, R y CO-group substitution; Among them, R y Can be selected from C1-C6 alkyl, C5-C7 aryl or heteroaryl; The above heterocycloalkyl and heteroaryl groups contain 1 to 3 heteroatoms, each of which is independently selected from N, O, or S; Represents possible chemical bonds.

2. A compound of formula II, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof: Wherein Y1 is selected from C1-C6 alkyl, 3-7 membered cycloalkyl, 3-7 membered heterocycloalkyl, -NR1R2, 6-14 membered aryl, 5-12 membered heteroaryl; wherein when Y1 is selected from 3-7 membered cycloalkyl or 3-7 membered heterocycloalkyl, each is optionally substituted by one or more groups selected from C1-C6 alkyl, halogen, cyano, C1-C6 alkoxy, -NHCOR1, amino, hydroxyl or NR1R2; wherein when Y1 is selected from 6-14 membered aryl or 5-12 membered heteroaryl, each is optionally substituted by one or more Rx groups, the Rx groups are selected from C1-C6 alkyl, cyano, halogen, C1-C6 alkoxy, -NR1COR2, C2-C6 alkynyl, amino, hydroxyl, NR1R2 or C2-C6 alkenyl substituted groups, or the Rx groups form a 9-10 membered cyclic ring with Y1; wherein the 3-7 membered heterocycloalkyl or 5-12 membered heteroaryl each independently contains 1-3 heteroatoms selected from N, O or S; R1 or R2 are each independently selected from H or C1-C3 alkyl; Represents possible chemical bonds.

3. A compound of formula III, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof: wherein Y3 is selected from 3-7 membered cycloalkyl, 4-10 membered heterocycloalkyl, 5-8 membered aryl, 5-8 membered heteroaryl, 5-7 membered aryl and 5-7 membered heterocycloalkyl; or Y3 is selected from 3-12 membered cycloalkyl or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl may be monocyclic or polycyclic; or Y3 is selected from a 5-16 membered aryl or heteroaryl group, wherein the aryl or heteroaryl group may be monocyclic or polycyclic, and at least part of the polycyclic rings are aromatic; Optionally, Y3 is further substituted by one or more selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl, 5-8 membered aryl, 5-7 membered heteroaryl, halogen, cyano, amino, C1-C6 alkoxy, R y CO-substituted; wherein R y Can be selected from C1-C6 alkyl, C5-C7 aryl or heteroaryl; wherein the heterocycloalkyl and heteroaryl groups each independently contain 1 to 3 heteroatoms selected from N, O, or S; Represents possible chemical bonds.

4. A compound of formula IV, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof: in, Where a is 0, 1 or 2; R3 is selected from NR6R7, R6 and R7 can be independently selected from H, C1-C3 alkyl, C3-C6 cycloalkyl or C3-C6 heterocycloalkyl; R4 is selected from H or C1-C3 alkyl; or Y3 is selected from 3-12 membered cycloalkyl or heterocycloalkyl, wherein the cycloalkyl or heterocycloalkyl may be monocyclic or polycyclic; or Y3 is selected from a 5-16 membered aryl or heteroaryl group, wherein the aryl or heteroaryl group may be monocyclic or polycyclic, and at least part of the polycyclic rings are aromatic; Optionally, Y3 is further substituted by one or more selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl, 5-8 membered aryl, 5-7 membered heteroaryl, halogen, cyano, amino, C1-C6 alkoxy, R y Group substitution of CO-; Among them, R y Can be selected from C1-C6 alkyl, C5-C7 aryl or heteroaryl; The heterocycloalkyl and heteroaryl groups each independently contain 1 to 3 heteroatoms selected from N, O, or S.

5. The compound according to claim 1, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein L is selected from 6-10 membered aryl, 5-10 membered heteroaryl or 6-10 membered heterocycloalkyl, and X is absent.

6. The compound according to claim 5, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein L is selected from substituted or unsubstituted oxacyclohexyl, C1-C6 alkyl, cyclopropyl, phenyl, indazolyl, oxoindoleyl, 1,3-dihydro-oxo-benzimidazolyl, and X is absent.

7. The compound according to any one of claims 1 or 2, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein L is selected from 3-6 membered monocycloalkyl, 6-10 membered cycloalkyl, and X is selected from -NHSO2Y1, -NHCOY2.

8. The compound according to claim 7, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein L is selected from cyclohexyl, oxacyclohexyl, cyclopropyl, tert-butyl, phenyl, indazolyl, oxoindoleyl, 1,3-dihydro-oxo-benzimidazolyl.

9. The compound according to claim 7 or 8, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein Y1 is selected from methyl, ethyl, propyl, isopropyl, tert-butyl, azetidinyl, oxetanyl, -NR1R2, azetidinyl, phenyl, pyridyl, pyrazolyl, cyclobutyl, quinolyl, isoquinolyl, cyclopentyl, cyclohexyl, thiazolyl, furanyl, thienyl, imidazolyl, pyrimidinyl, oxoindolyl, oxotetrahydroisoquinolyl, indolyl, oxotetrahydroquinolyl.

10. The compound according to claim 7 or 8, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein Y1 is selected from the following structures:

11. According to the compound of claim 9, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, Y1 is further substituted by a group selected from halogen, cyano, C1-C3 methyl, ethynyl, -NHCOCH3, C1-C3 methoxy, -NCH3COCH3.

12. According to the compound of claim 11, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, Y1 is further substituted by a substituent selected from F, Cl, Br, cyano, methyl, ethyl, ethynyl, -NHCOCH3, methoxy, ethoxy, propoxy, isopropoxy, -NCH3COCH3.

13. According to the compound of claim 1 or 7, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, Y2 is selected from methyl, ethyl, propyl, isopropyl, tert-butyl, -NHCO(CH3)2, -CONHCH3, -NHCOCH2C(CH3)3 or -N(CH3)2.

14. The compound according to claim 1 or 4, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein R6 and R7 are both H; or R6 is H and R7 is selected from C1-C3 alkyl; or R6 is H and R7 is selected from methyl, ethyl, n-propyl or isopropyl.

15. The compound according to any one of claims 1, 3-4 or 14, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein Y3 is selected from a 5-13 membered aryl or heteroaryl group, wherein the aryl or heteroaryl group may be a monocyclic or fused bicyclic ring; The number of heteroatoms in the heteroaryl group is 1-3, and each heteroatom is independently selected from N, O or S.

16. The compound according to claim 15, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein Y3 is selected from furanyl, thienyl, pyrrolyl, pyridyl, pyrazinyl, phenyl, pyrimidinyl, quinolyl, isoquinolyl, purinyl, benzopyrrolyl, benzofuran, benzothiophene and benzimidazole.

17. According to the compound of claim 15 or 16, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or their mixture, the Y3 can be substituted at any possible position by one or more groups selected from fluorine, chlorine, bromine, iodine, cyano, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, cyclohexyl, methoxy, ethoxy, n-propoxy, isopropoxy, CH3CO-.

18. A compound having the structure shown below, or a pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof:

19. A pharmaceutical composition comprising the compound shown in any one of 1-18, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, and a pharmaceutically acceptable excipient and / or carrier.

20. Use of the compound according to any one of claims 1 to 18, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, or the pharmaceutical composition according to claim 19 for preparing a drug for preventing or treating diseases related to the interaction with Menin-MLL protein.

21. The use according to claim 20, wherein the related diseases include leukemia, leukemia-related complications, lymphoma, solid tumors or diabetes.

22. The use according to claim 20, wherein the leukemia comprises acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia or myelodysplastic syndrome.

23. The use according to claim 22, wherein the acute myeloid leukemia comprises mixed rearrangement leukemia or nucleoside phosphorylation enzyme 1 (NPM1) mutation leukemia.

24. The use according to claim 21, wherein the leukemia-related complications include leukemic meningitis.

25. The use according to claim 21, wherein the solid tumors include pancreatic cancer, colon cancer, liver cancer, glioblastoma, lung cancer, breast cancer, and prostate cancer.

26. The use according to claim 21, wherein the lymphoma comprises Hodgkin's lymphoma, non-Hodgkin's lymphoma, plasma cell tumor, multiple myeloma, cutaneous T-cell lymphoma, and lymphoid tumor.